Skip to main content

View full-text article in PMC

. 2005 May 14;11(18):2748–2753. doi: 10.3748/wjg.v11.i18.2748

Table 2.

IC₅₀ values of chemotherapeutic agents on CCA cell lines.

Drug	IC₅₀ (mmol/L)
	Poorly differentiated		Moderately differentiated		Well differentiated
	KKU-100	KKU-M055	KKU-M156	KKU-M214	KKU-OCA17
Anthracyclins
Doxorubicin	2.3±0.8^b	0.04±0.02	1.8±1.0b	0.25±0.05	0.84±0.83
Pirarubicin	0.27±0.22^a	0.01±0.01	0.35±0.06^b	0.17±0.03^b	0.13±0.05^b
Platinum derivatives
Cisplatin	37±3^b	0.05±0.01	222±38^b	130±12^b	6.22±0.19^b
Carboplatin	13±3^b	0.26±0.01	229±36^b	107±4^b	10.4±2.7^a
Oxaliplatin	71.7±38.7^a	0.11±0.00	7.0±4.7	38.0±6.7^b	6.8±1.3^b
Pyrimidine analog
5-Fluorouracil	1 018±326^d	46±42^c	144±55^d	29.1±17.6^b	3.46±0.91
Taxanes
Paclitaxel	39.0±6.8^b	0.0030±0.0001	10.9±5.8^a	2.62±0.75^a	12.5±1.9^b
Docetaxel	41.2±7.2^b	0.00002±0.00002	0.80±0.36^a	12.4±3.7^a	1.3±0.3^b
Vinca-alkaloids
Vincristine	216.2±52.1^d	2.05±0.68^c	0.97±0.64	85±19^d	0.82±0.17
Vinorabine	2.1±0.2^b	0.13±0.01	0.23±0.01^a	164±120	0.64±0.17^a
Others
Etoposide	416±131^b	0.04±0.01	274±217^b	54±26^a	126±88^a
Irinotecan	23±6^a	3.41±0.51	13.1±2.1^b	43±9^b	3.60±1.16
Mitomycin C	45±2^b	0.01±0.00	187±0^b	78±32^a	5.07±0.17^b

Data represents mean±SD of at least three experiments.

^a

P<0.05,

^b

P<0.01 vs KKU-M055;

^c

P<0.05,

^d

P<0.01 vs KKU-OCA17.